51³Ô¹ÏºÚÁÏ

A group of six leading Alzheimer’s experts have convened to make the first recommendations for the appropriate use of aducanumab (Aduhelm, Biogen/Eisai), a newly approved treatment for early Alzheimer’s disease.

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that three scientific presentations in dementia-related psychosis (DRP) will be shared at the Alzheimer’s Association International Conference® 2021 (AAIC®), being held July 26-30, 2021 in Denver, Colo., and virtually.

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that three scientific presentations in dementia-related psychosis (DRP) will be shared at the Alzheimer’s Association International Conference® 2021 (AAIC®), being held July 26-30, 2021 in Denver, Colo., and virtually.

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that three scientific presentations in dementia-related psychosis (DRP) will be shared at the Alzheimer’s Association International Conference® 2021 (AAIC®), being held July 26-30, 2021 in Denver, Colo., and virtually.

Just a month after it gave the new Alzheimer's drug aducanumab (Aduhelm) the green light, the FDA decided to change the label.

Alzheimer’s patients and their loved ones have a renewed sense of hope now that the U.S. Food & Drug Administration approved the first Alzheimer’s drug in nearly two decades.

The FDA’s approval of Biogen’s Alzheimer’s drug Aduhelm was a landmark moment in the life of Dr. Paul Aisen.

Now that the FDA has approved Biogen's aducanumab (Aduhelm), the controversial new drug for Alzheimer's disease, what does this mean?